In our latest article we review best practices & future perspectives for the identification of pts with HER2-low BC. Thanks to AZ for support and to H. Earle for bravely sharing with us and the ESMO Open readers her experience during treatment with T-DXd. esmoopen.com/article/S2059-…

Results of the Phase II #PACEStudy : Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- #MetastaticBreastCancer were presented at #AACR24 . Erica Mayer Meredith Regan, ScD Sara Tolaney Rinath Jeselsohn Massimo Cristofanilli, MD, FACP Lorenzo Gerratana
abstractsonline.com/pp8/#!/20272/p…

🔥 Results of phase 3 ALINA study now published in NEJM

2 yrs adjuvant alectinib v chemotherapy

✅ DFS HR 0.24
✅ 🧠 DFS HR 0.22

IMO, practice changing for our patients w/ ALK positive early-stage NSCLC

ALK Positive ALK+ International OncoAlert #lcsm

Summary of approved BCMA agents #mmsm 👇

✅ Ide cel seems inferior to BsABs and Cilta cel at later lines (In ≥4 lines, no role for Ide cel IMO)

✅In <4 lines with triple/penta refractory:Cilta cel (commercial) or clinical trial of BsAbs until approved(no role for Ide cel IMO)

Tomorrow (04/09), join me and Enrique Soto for a discussion on Geriatric Assessment at the IPOS webinar!

Don't miss out, sign up now: ipos-society.org/event-5596691

Tania Estapé

🚨HIGHLY recommended for any medical student or resident planning a career in oncology and interested in developing an 🌟invaluable🌟 skillset as a palliative care physician. Jacob J. Adashek, DO Fernando Diaz, MD Ramy Sedhom, MD Ana I. Velázquez Mañana, MD MSc (she/her/ella) ASCO

Join Roswell Park's Chair of Thoracic Surgery Sai Yendamuri, MD, as he presents at #AACR24 .

📍: Room 30, Upper Level, San Diego Convention Center
⏰ : Mon. 4/8 at 10:45 AM – 11:05 AM PDT

Learn more: abstractsonline.com/pp8/#!/20272/p….

#TDxD now U.S. FDA approved for pan-tumor w/ HER2 IHC3+ solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02:

- Dose 5.4 mg/kg
- Common AE: fatigue,…

Out in The Lancet the results of thePHERgain study showing impressive 3-y IDFS rate

A PET-based, pCR-adapted strategy could help identify patients with HER2-positive EBC who could safely omit chemotherapy

OncoAlert

thelancet.com/journals/lance…

Just out CA: A Cancer Journal for Clinicians

'Global cancer statistics 2022: #GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries'

Global maps showing the most common type of cancer mortality among men and women 👇

Lung cancer shown in Blue

American Cancer Society

Our study on the prognosis of small TNBCs is out in npj Journals Breast. Among 8601 pts with stage I TNBC in SEER, we found excellent 5-year outcomes, with a significant BCSS benefit with chemo for pT1c. Benefit less clear in tumors <1cm: biomarkers needed! nature.com/articles/s4152…

Honored to be the next chair of ASCO ASCOTECAG and follow in the amazing footsteps and leadership of Fernando Diaz, MD!!!

Very grateful👏🏻for all of the amazing mentors who have helped me along the way Razelle Kurzrock, MD Sumanta K. Pal, MD, FASCO Vivek Subbiah, MD Jun Gong jc gilberto lopes ❤️

Check out my blog post here:

shorturl.at/coJZ5

Great news in the NEJM for patients with breast cancer!!
nejm.org/doi/full/10.10…

A memorable day where the Hon'ble President dedicated India's first CAR-T therapy to the nation. Frugal innovation, a result of a great collaboration between Tata Memorial Hospital & IIT Bombay with the team led by Rahul Purwar Hasmukh Jain Gaurav Narula MD culminating in ImmunoACT

Pleased to be featured in ASCO Connection today.

I shared my experiences on ASCO’s Virtual Mentorship Program 👨🏽‍⚕️🙌🏽

My mentor was Muhammad Salman Faisal. He is one of the nicest physicians I’ve ever met, and someone who has definitely inspired me to pursue a career in oncology.

#ESMOBreast24 : Hope Rugo has been bestowed with the 2024 ESMO Breast Cancer Award for her exceptional contributions to #BreastCancer clinical research.
She will deliver her award lecture on 16 May at #ESMOBreast24 .
📌 ow.ly/IBw650R8cI4

❓Can completion axillary-lymph-node dissection be omitted in breast cancer with T1-3, clinically node-negative, 1 or 2 positive sentinel nodes?
NEJM

✅Positive study, omittion is non-inferior to ALND
✅5-year recurrence-free survival: 89.7% vs. 88.7%, HR: 0.89 (95% CI, 0.66…

TP53-associated early breast cancer

227 pts, mFU: 70 mo

mAge➡️37
HR+/HER2-➡️40.9%
HR+/HER2+➡️34.4%

5y RFS (HR+/HER2)➡️61.1%!!
5y radiation-induced sarcoma➡️4.8%‼️

Quite an informative analysis. Congrats to all the researchers

OncoAlert JNCI
academic.oup.com/jnci/article-a…

Check out our article featured in #ASCOdailyNews 'Improving Outcomes for Early-Stage NSCLC Using Targeted Therapy'

A big shout-out to Dr. Vanya Aggarwal, a second-year fellow at Georgetown Lombardi, for her great work

ASCO

Link: bit.ly/3xio5LI